SCHEMBL3056744

SCHEMBL3056744

COc1ccc(NC(C)=O)c(C)n1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.56
TSHR P16473 1/20 0.56
NNMT P40261 1/20 0.51
CYP1A2 P05177 1/20 0.50
PDE10A Q9Y233 2/20 0.44
SMN1; SMN2 Q16637 4/20 0.43
HSD17B1 P14061 1/20 0.42
HSD17B2 P37059 1/20 0.42
MAPT P10636 3/20 0.42
POLB P06746 2/20 0.42
PI4KB Q9UBF8 2/20 0.42
HPGD P15428 1/20 0.42
MAPK1 P28482 1/20 0.42
TDP1 Q9NUW8 1/20 0.41
MTNR1A P48039 2/20 0.41
MTNR1B P49286 2/20 0.41
P2RX7 Q99572 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28692390 0.90 ALDH1A1 (0.48) ALDH1A1TSHRNNMTCYP1A2PDE10A
Ethyl Acetate SCHEMBL31489594 0.90 ALDH1A1 (0.48) ALDH1A1TSHRNNMTCYP1A2PDE10A
SCHEMBL4254971 0.80 CYP1A2 (0.47) ALDH1A1TSHRNNMTCYP1A2PDE10A
SCHEMBL17916965 0.79 ALDH1A1 (0.43) ALDH1A1TSHRCYP1A2SMN1; SMN2MAPT
SCHEMBL10124284 0.78 ALDH1A1 (0.50) ALDH1A1TSHRCYP1A2SMN1; SMN2MAPT
SCHEMBL15826018 0.77 ALDH1A1 (0.49) ALDH1A1NNMTCYP1A2SMN1; SMN2MAPT
SCHEMBL10565518 0.76 CYP1A2 (0.50) ALDH1A1TSHRNNMTCYP1A2PDE10A
SCHEMBL1904978 0.76 NNMT (0.46) NNMTCYP1A2PDE10APOLBTDP1
SCHEMBL13298958 0.75 GAA (0.56) ALDH1A1MAPTPOLBHPGDTDP1
SCHEMBL3508924 0.75 ALDH1A1 (0.47) ALDH1A1TSHRMAPTPOLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12486234-B2 PAPD5 inhibitors and methods of use thereof CHILDREN'S MEDICAL CENTER CORPORATION (US) 2025-12-02 US disclosed
CN-119798159-A PAPD5 inhibitors and methods of use thereof 儿童医学中心公司 2025-04-11 CN disclosed
US-20220274928-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF CHILDREN'S MEDICAL CENTER CORPORATION 2022-09-01 US disclosed
EP-3959197-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF CHILDREN'S MEDICAL CENTER CORPORATION (US) 2022-03-02 EP disclosed
CN-113993848-A Inhibitors of PAPD5 and methods of use thereof 儿童医学中心公司 2022-01-28 CN disclosed
WO-2020219729-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF CHILDREN'S MEDICAL CENTER CORPORATION (US) 2020-10-29 WO disclosed
WO-2020219729-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF CHILDREN'S MEDICAL CENTER CORPORATION (US) 2020-10-29 WO disclosed
EP-3498696-A1 ENANTIOMERICALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO PARASITICIDAL COMPOUNDS Merial, Inc. (US) 2019-06-19 EP disclosed
EP-3050874-B1 ENANTIOMERIALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO PARACITICIDAL COMPOUNDS MERIAL INC (US) 2019-01-09 EP disclosed
WO-2010056999-A9 ENANTIOMERICALLY ENRICHED ARYLOAZOL- 2 -YL CYANOETHYLAMINO PARACITICIDAL COMPOUNDS MERIAL LIMITED (US) 2018-06-07 WO disclosed
EP-3050874-A1 ENANTIOMERIALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO PARACITICIDAL COMPOUNDS Merial, Inc. (US) 2016-08-03 EP disclosed
EP-2364301-B1 ENANTIOMERICALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO PARACITICIDAL COMPOUNDS MERIAL LTD (US) 2015-09-02 EP disclosed
US-8461176-B2 Enantiomerically enriched aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof MERIAL LIMITED (US) 2013-06-11 US disclosed
US-20100160391-A1 Substituted Aminopyridines as Fluorescent Reporters for Amide Hydrolases NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-06-24 US disclosed
US-20100160391-A1 Substituted Aminopyridines as Fluorescent Reporters for Amide Hydrolases NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-06-24 US disclosed
US-20100125089-A1 ENANTIOMERICALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF MERIAL, INC. 2010-05-20 US disclosed
WO-2008008732-A2 SUBSTITUTED AMINOPYRIDINES AS FLUORESCENT REPORTERS FOR AMIDE HYDROLASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220274928-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF POT1, PARP15, TERT ALDH1A1 2425/4885TSHR 3815/4885NNMT 629/4885
US-12486234-B2 PAPD5 inhibitors and methods of use thereof POT1, PARP15, TERT ALDH1A1 2425/4885TSHR 3815/4885NNMT 629/4885
US-20100125089-A1 ENANTIOMERICALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF CYP4B1, NPY4R, CYP4X1 ALDH1A1 1144/4885TSHR 745/4885NNMT 2041/4885
US-20100160391-A1 Substituted Aminopyridines as Fluorescent Reporters for Amide Hydrolases APEH, AADAC, NAALAD2 ALDH1A1 276/4885TSHR 3306/4885NNMT 726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.